Product

Tavilermide

Aliases

5% Tavilermide ophthalmic solution

2 clinical trials

3 indications

Indication

Dry Eye Syndrome

Indication

Keratoconjunctivitis sicca

Indication

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled Clinical Study to Assess the Efficacy and Safety of 5% Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Status: Active (not recruiting), Estimated PCD: 2024-05-01

Clinical trial

Multi-Center, Randomized,Double-Masked, Vehicle-Controlled Study to Assess the Safety and Efficacy Study of Tavilermide Ophthalmic Solutions for the Treatment of Dry Eye

Status: Completed, Estimated PCD: 2020-06-11